Comparison of SF-36 and WHOQoL-BREF in Measuring Quality of Life in Patients with Type 2 Diabetes
Received 20 April 2020
Accepted for publication 30 June 2020
Published 11 August 2020 Volume 2020:13 Pages 497—506
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Scott Fraser
Abbas Abbasi-Ghahramanloo, 1 Mojtaba Soltani-Kermanshahi, 2 Kamyar Mansori, 3 Maryam Khazaei-Pool, 4, 5 Masoudreza Sohrabi, 6 Hamid Reza Baradaran, 7, 8 Zahra Talebloo, 9 Ali Gholami 10, 11
1Department of Public Health, School of Health, Ardabil University of Medical Sciences, Ardabil, Iran; 2Social Determinants of Health Research Center, School of Medicine, Semnan University of Medical Sciences, Semnan, Iran; 3Department of Biostatistics and Epidemiology, School of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran; 4Department of Public Health, School of Health, Mazandaran University of Medical Sciences, Sari, Iran; 5Health Sciences Research Center, Addiction Research Institute, Mazandaran University of Medical Sciences, Sari, Iran; 6Gastrointestinal & Liver Disease Research Center (GILDRC), Firoozgar Hospital, Iran University of Medical Sciences, Tehran, Iran; 7Department of Epidemiology, School of Health, Iran University of Medical Sciences, Tehran, Iran; 8Ageing Clinical and Experimental Research Team, Institute of Applied Health Sciences, School of Medicine, Medical Sciences & Nutrition University of Aberdeen, Aberdeen, UK; 9Non-Communicable Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran; 10Noncommunicable Diseases Research Center, Neyshabur University of Medical Sciences, Neyshabur, Iran; 11Department of Epidemiology & Biostatistics, School of Public Health, Neyshabur University of Medical Sciences, Neyshabur, Iran
Correspondence: Ali Gholami Janbazan Ave, Neyshabur, Iran
Objective: This study aimed to compare the quality of life (QoL) in patients with type 2 diabetes using two WHOQoL -BREF and SF-36 questionnaires in Iran.
Patients and Methods: In this cross-sectional study, 1847 patients with type 2 diabetes were recruited from rural health-care centers affiliated to Neyshabur County (Iran) in 2012. In addition to demographic information, two questionnaires WHOQoL-BREF and SF-36 questionnaires were used for data collection. Cronbach’s alpha coefficient was used for scale reliability. We conducted an exploratory factor analysis for the investigation of construct validity. Convergent and discriminant validity were analyzed using Spearman correlation coefficient. To determine the relationships between the eight domains of SF-36 and four domains of the WHOQoL-BREF, structural equation modelling was performed.
Results: Cronbach’s alpha coefficients were acceptable for all domains of both WHOQoL-BREF (0.69– 0.86) and SF-36 (0.63 − 0.92) questionnaires. The principal component analysis showed two separate factors: one for all domains of SF-36 and another for all domains of WHOQoL-BREF. Spearman correlation coefficients of both instruments were partly to strongly correlated with most domains (r ≥ 0.40). Correlations for domains with similar constructs were stronger than those measuring varied constructs. Structural equation modelling recommended approximately moderate relationships among the SF-36 and WHOQoL-BREF domains.
Conclusion: Our study suggests that SF-36 and WHOQoL-BREF are reliable instruments for clinical and research uses, respectably. However, results of the goodness of fit showed that the WHOQoL-BREF was fitted well. Also, the WHOQoL-BREF can be considered more suitable for the study population.
Keywords: quality of life, type 2 diabetes, WHOQoL-BREF, SF-36, Iran
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]